Amryt Pharma (Amryt Pharma) Total Liabilities : $412.6 Mil (As of Sep. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Total Liabilities?

Amryt Pharma's Total Liabilities for the quarter that ended in Sep. 2022 was $412.6 Mil.

Amryt Pharma's quarterly Total Liabilities declined from Mar. 2022 ($440.89 Mil) to Jun. 2022 ($422.71 Mil) and declined from Jun. 2022 ($422.71 Mil) to Sep. 2022 ($412.60 Mil).

Amryt Pharma's annual Total Liabilities increased from Dec. 2019 ($395.26 Mil) to Dec. 2020 ($470.45 Mil) but then declined from Dec. 2020 ($470.45 Mil) to Dec. 2021 ($459.40 Mil).

Amryt Pharma Total Liabilities Historical Data

The historical data trend for Amryt Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Total Liabilities Chart

Amryt Pharma Annual Data

Trend

Mar12

Mar13

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Total Liabilities

Get a 7-Day Free Trial

69.83

84.53

395.26

470.45

459.40

Amryt Pharma Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Total Liabilities	Get a 7-Day Free Trial															549.44	459.40	440.89	422.71	412.60

Amryt Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Amryt Pharma's Total Liabilities for the fiscal year that ended in Dec. 2021 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	157.279	+	(199.183	+	85.162
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	17.772	+	0)
	=	459.4

Total Liabilities	=	Total Assets (A: Dec. 2021 )	-	Total Equity (A: Dec. 2021 )
	=	816.057	-	356.661
	=	459.4

Amryt Pharma's Total Liabilities for the quarter that ended in Sep. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	143.144	+	(211.825	+	51.82
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	5.809	+	0)
	=	412.6

Total Liabilities	=	Total Assets (Q: Sep. 2022 )	-	Total Equity (Q: Sep. 2022 )
	=	736.875	-	324.277
	=	412.6

Amryt Pharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Amryt Pharma (Amryt Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH

Website

http://www.amrytpharma.com

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).